Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Food-effect Study of Weekly Administration of (bi-)Daily Oral Docetaxel (ModraDoc006) in Combination With Ritonavir

Trial Profile

Food-effect Study of Weekly Administration of (bi-)Daily Oral Docetaxel (ModraDoc006) in Combination With Ritonavir

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel/ritonavir (Primary) ; Ritonavir (Primary)
  • Indications Advanced breast cancer; Anal cancer; Bladder cancer; Carcinoma; Cervical cancer; Gastric cancer; Head and neck cancer; Neuroendocrine carcinoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Pharmacokinetics
  • Sponsors Modra Pharmaceuticals
  • Most Recent Events

    • 19 Jan 2021 Status changed from active, no longer recruiting to completed as per resultspublished in the Drugs in R and D.
    • 19 Jan 2021 Results published in the Drugs in R and D.
    • 25 Mar 2019 Planned End Date changed from 1 Feb 2019 to 1 Jul 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top